JAK2 mutations, especially V617F, play a critical role in MPN pathogenesis and drug resistance; however, JAK2 inhibitor monotherapy is largely ineffective in achieving consistent remission in MPN patients carrying these mutations. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.